PTEN and cancer: Developing novel drug strategies for these p53 targets influencing tumorigenesis and cancer stemness will be challenging and necessitate a critical understanding of the p53, p53 isomers and mutp53 upstream and downstream stem pathways and interacting partners, such as PTEN and MDM2.